Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

@article{Stavenhagen2007FcOO,
  title={Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.},
  author={Jeffrey B. Stavenhagen and Sergey Gorlatov and Nadine Tuaillon and Christopher T. Rankin and Hua Li and Stephen Burke and Ling Huang and Sujata Vijh and Shantelle Johnson and Ezio Bonvini and Scott J. Koenig},
  journal={Cancer research},
  year={2007},
  volume={67 18},
  pages={
          8882-90
        }
}
Monoclonal antibodies (mAb) are widely used in the treatment of non-Hodgkin's lymphoma and autoimmune diseases. Although the mechanism of action in vivo is not always known, the therapeutic activity of several approved mAbs depends on the binding of the Fcgamma regions to low-affinity Fcgamma receptors (FcgammaR) expressed on effector cells. We did functional genetic screens to identify IgG1 Fc domains with improved binding to the low-affinity activating Fc receptor CD16A (FcgammaRIIIA) and… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 96 CITATIONS, ESTIMATED Infinity% COVERAGE

96 Citations

051015'09'12'15'18
Citations per Year
Semantic Scholar estimates that this publication has 96 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…